This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read 89bio’s 8K filing here.
About 89bio
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
Featured Articles
- Five stocks we like better than 89bio
- What Makes a Stock a Good Dividend Stock?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Stock Market Sectors: What Are They and How Many Are There?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- What to Know About Investing in Penny Stocks
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
